Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (Nasdaq: CTKB) is a cell analysis solutions company focused on high-parameter flow cytometry using its patented Full Spectrum Profiling™ (FSP®) technology. This news page aggregates coverage of Cytek’s announcements so readers can follow developments related to its instruments, reagents, services and corporate activities.
Company press releases frequently address financial results and outlook, including quarterly revenue performance, recurring revenue trends from service and reagent businesses, and updates on installed instrument base. Cytek also issues news when it provides preliminary revenue expectations or reaffirms full-year guidance, and these items are often accompanied by Form 8-K filings summarizing results of operations.
Another major category of CTKB news involves product and technology updates. Recent communications have highlighted the launch of the Cytek Aurora™ Evo full spectrum flow cytometer, enhancements to small particle detection, and initiatives to expand access to advanced cytometry tools through instrument awards and research grants. The company also reports on the use of its FSP systems in peer-reviewed research and at scientific meetings.
Investors and researchers will also find corporate and recognition news, such as Cytek’s inclusion on TIME’s 2026 list of America’s Growth Leaders, expansion of its European headquarters in Amsterdam, and participation in healthcare and investor conferences hosted by organizations including UBS, Morgan Stanley, Stephens and Piper Sandler. Updates on collaborations with groups like the International Society for Advancement of Cytometry (ISAC) and presence at clinical cytometry conferences such as ESCCA and ICCS are also covered.
By reviewing CTKB news, users can track how Cytek communicates its financial performance, product evolution, geographic expansion and engagement with the scientific and investment communities over time.
Cytek Biosciences (Nasdaq: CTKB) reported Q2 2025 financial results, with total revenue of $45.6 million, marking a 2% decrease from Q2 2024. The company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025. Notable highlights include the launch of the Cytek Aurora™ Evo system and 16% growth in recurring revenue, which now accounts for 32% of trailing 12-month revenue.
The company reported a net loss of $5.6 million and Adjusted EBITDA of $1.3 million. Cash position remained strong at $262.0 million. Cytek repurchased $4.5 million of common stock during Q2 and narrowed its 2025 revenue guidance to $196-205 million, projecting -2% to +2% growth over 2024.
Cytek Biosciences (Nasdaq: CTKB) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day, where management will discuss quarterly results, business developments, and future outlook. Investors can access the live webcast through the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (NASDAQ: CTKB), a cell analysis solutions company, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. The company's management will engage in a fireside chat on June 11th at 11:40 a.m. PT / 2:40 p.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at two major industry events: CYTO 2025 and IMMUNOLOGY2025. The company will conduct demonstrations, educational workshops, and tutorials at both conferences.
At IMMUNOLOGY2025 (May 3-7 in Honolulu), Dr. Eleanor Kincaid will host a workshop on mouse immune response characterization. The company will display its complete cell analysis solutions, including instruments, reagents, Cytek® Cloud, software, and services at Booth 801.
As a Platinum sponsor at CYTO 2025 (May 31-June 4 in Denver), Cytek will showcase its technology at Booth 401. CEO Wenbin Jiang emphasizes the company's commitment to making spectral flow cytometry more accessible, focusing on high-growth areas like immunology, oncology, and cell therapy.
The company's FSP technology aims to streamline workflows, accelerate discoveries, and enhance efficiency in both research and clinical studies.
Cytek Biosciences (Nasdaq: CTKB) has announced its upcoming first quarter 2025 financial results release, scheduled for May 8, 2025, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss quarterly results, business developments, and future outlook. Interested parties can access the live audio webcast through the 'Investors' section on the company's website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has launched the Cytek® Muse® Micro, a next-generation cell analyzer that enhances their iconic Guava® Muse® system. This affordable flow cytometry instrument features a user-friendly design and advanced capabilities for cell analysis applications.
The Muse Micro system includes a 488 nm blue laser with five parameters and three fluorescent channels. Key features include a compact 8x10-inch design, advanced microcapillary technology, pre-optimized kits, and Cytek InCyte™ software for simplified data analysis.
The system targets diverse markets including cell and gene therapy, drug discovery, water quality testing, biopharma, bioprocessing and beverage production. Building on the success of the original 2013 Muse system, this new analyzer aims to make sophisticated cell analysis more accessible while sustaining growth of Cytek's reagent business through additional channels.
Cytek Biosciences (CTKB) reported its Q4 and full-year 2024 financial results, showing mixed performance. Total revenue reached $200.5 million for FY2024, a 3.9% increase from 2023. The company expanded its installed base to 3,034 instruments, with 667 placements in 2024.
The company reported a net loss of $6.0 million in 2024, improved from a $12.1 million loss in 2023. Adjusted EBITDA grew significantly to $22.4 million, up 77% year-over-year. Notable developments include opening a new manufacturing facility in Singapore and completing a share repurchase of 3,971,624 shares for $21.6 million.
Looking ahead to 2025, Cytek projects revenue between $204-212 million, representing 2-6% growth. The company also announced an additional $50 million stock repurchase program for 2025.
Cytek Biosciences (Nasdaq: CTKB) has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results, business developments, and outlook. Interested parties can access the live audio webcast through the 'Investors' section of Cytek's website at investors.cytekbio.com.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
